The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Building trust and acceptance of a licensed vaccine among the public is a task of communication by governments and healthcare personnel to ensure a vaccination campaign proceeds smoothly, saves lives, and enables economic recovery. When a vaccine is licensed, it will initially be in limited supply due to variable manufacturing, distribution, and logistical factors, requiring an allocation plan for the limited supply and which population segments should be prioritized to first receive the vaccine.
== Vapor-ion, charge transfer reaction == The analytes are in the vapor phase. This includes breath, odors, VOCs, and other molecules with low volatility that, due to the constant improvements in sensitivity, are detectable in the vapor phase despite their low vapor pressure. Analyte ions are produced via gas-phase chemical reactions, where charging agents collide with the analyte molecules and transfer their charge. In secondary electro-spray ionization (SESI), a nano-electrospray operated at high temperature produces nanodroplets that evaporate very rapidly to produce ions and protonated water clusters that ionize the vapors of interest. SESI is commonly used for the analysis of trace concentrations of vapors being able to detect low volatility species in the gas phase with molecular masses of up to 700 Da.
October 8 – The US begins direct negotiations with the military junta while continuing sanctions against its leader, Min Aung Hlaing, for human rights violations, notably the Rohingya genocide. The Pentagon instructs the US Central Command to get ready in case direct military operations against Iran were to resume. U.S. and Israeli officials suggests that joint strikes against Iranian nuclear, energy, and infrastructure sites might take place prior to either the November US midterm elections or the late October Israeli general election, even though Trump had not made a final decision or established a timeline. Internal assessments and energy analysts cautions that renewed hostilities would fail to lower immediate gasoline prices and could instead cause a sharp spike in global oil prices, despite the administration's goal of a military breakthrough to eventually lower domestic fuel costs. Further sanctions are put by the US on Iran's shadow fleet.
Because lipopolysaccharides are potent inflammatory agents, and the action of antibiotics can result in the release of these compounds, the binding capacity of BPI was explored as a possible means of reducing injury. Xoma Ltd. developed a recombinant 21kDa portion of the BPI molecule called rBPI21, NEUPREX, or opebecan. In a trial, it was found to decrease the mortality of Gram-negative bacterial-induced sepsis. Studies suggest that its binding activity is not the means by which it mediates its protective effect. Studies show biological effects with Gram-positive bacteria and even in infection by the protozoan, Toxoplasma gondii. The N-terminal portion of murine BPI (199 amino acids) genetically fused to Halobacterium sp. NRC-1 GvpC protein was bound to the surface of gas vesicle nanoparticles (GVNPs) and tested for protective activity using a murine model of endotoxic shock. Depending on the time of delivery and exposure to lethal concentrations of lipopolysaccharide (LPS) and D-galactosamine, the treatment resulted in increased survival and reduced symptoms of inflammation, including inflammatory anemia, recruitment of neutrophils, liver apoptosis as well as increased pro-inflammatory serum cytokine levels. When administered via footpad and before LPS exposure, there was 100% survival of the experimental cohort.
Sources: en.wikipedia.org
== External links == CID 6526396 from PubChem – cefpodoxime proxetil Vantin Tablets and Oral Suspension Torpod (Torrent) Full U.S. Prescribing Information (from manufacturer's website) Simplicef (from manufacturer's website) Intas Pharmaceuticals Ltd. » Animal Health :: Intas - a leading global pharmaceutical formulation development, manufacturing and marketing company
=== July === 1 July – The ESA space telescope Euclid is launched, beginning a six-year mission to study dark energy and dark matter. 3 July – Researchers demonstrate encoding and storing data – small images – as DNA without new DNA synthesis by recording light exposure into bacterial DNA via optogenetic circuits. The 'biological camera' extends chemical and electrical interface techniques. 5 July Harvard astronomer Avi Loeb reports the possibility of a Galileo project expedition having found first interstellar material. A first evolution experiment of synthetic 'minimal cells' – JCVI-syn3B bacterial cells whose genomes were trimmed to 493 essential genes and are the smallest of any known free-living organism – shows they survive and mutate vitally with their >50% decrease in fitness to JCVI-syn1 being regained after ~2,000 generations under accelerated evolution. 6 July – A study indicates release of methane from Arctic glacial retreat will result in Arctic emissions much higher than expected.
Elevated levels of kynurenic acid compared to kynurenine appear to be associated with poorer T cell response and higher mortality in male subjects with COVID-19, suggesting an explanation for the poorer clinical outcomes observed in males than in females.
=== Schools === Le Havre is located in the Academy of Rouen. The city operates 55 kindergartens (254 classes) and 49 communal primary schools (402 classes). The department manages 16 colleges and the region of Normandy manages 9 schools. The Jules Valles college in Caucriauville is classified as a sensitive institution and eleven colleges are in a priority education zone (ZEP). A boarding school of excellence, the Claude Bernard college, opened in 2011. The first college in Le Havre dates to the 16th century, the high school François I was founded during the Second Empire and is the oldest in Le Havre. The philosopher Jean-Paul Sartre (1905–1980) and Raymond Aron (1905–1983) taught there. The writer Armand Salacrou (1899–1989) studied in this institution.
Indoor combustion, such as for cooking or heating, is a major cause of indoor air pollution and causes significant health harms and premature deaths. Hydrocarbon fires cause air pollution. Pollution is caused by both biomass and fossil fuels of various types, but some forms of fuels are more harmful than others. Indoor fire can produce black carbon particles, nitrogen oxides, sulfur oxides, and mercury compounds, among other emissions. Around 3 billion people cook over open fires or on rudimentary cook stoves. Cooking fuels are coal, wood, animal dung, and crop residues. IAQ is a particular concern in low and middle-income countries where such practices are common. Cooking using natural gas (also called fossil gas, methane gas or simply gas) is associated with poorer indoor air quality. Combustion of gas produces nitrogen dioxide and carbon monoxide, and can lead to increased concentrations of nitrogen dioxide throughout the home environment which is linked to respiratory issues and diseases.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.